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Treatments for severe psoriasis: update
In March 2009 it was announced that efalizumab would be withdrawn from the Australian market. This follows a review of the drug in Europe which found the benefits no longer outweigh the risk of harm. There are reports of progressive multifocal leucoencephalopathy arising in patients who have been treated with efalizumab for more than three years. 1 The drug has also been under review in the USA. 2 
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